•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP) has provided a commercialization update, saying it has completed development of its QAI physiological AI clinical platform and begun outreach to prospective facility partners in Canada and the United States. The company said the platform is patent-protected and available for immediate deployment, and that it is actively pursuing its first signed evaluation agreement.
The company describes the QAI Platform as able to identify the probable substance a person has consumed—alcohol, opioid, benzodiazepine, stimulant, or cannabis—using only a standard laptop camera in real time, without a blood test, breathalyzer, or urine sample. It also said the system flags discrepancies when physiological readings do not match self-reported information and generates a documented clinical alert before intake is complete, with the stated potential to help prevent withdrawal-related deaths in custody.
QScreen AI said the platform simultaneously administers 13 validated clinical instruments, including CIWA-Ar, COWS, C-SSRS, LSI-R, and PREA-R. The company stated the system produces NCCHC-compliant documentation and delivers a complete risk-stratified intake summary in under seven minutes, without hardware installation and without an IT project.
The company said it holds a granted US patent on physiological impairment screening. It also reported that the platform has processed more than 720,000 real-world scans across global deployments, including tier-1 live-event deployments and workplace safety installations across multiple jurisdictions.
In Canada, QScreen AI said it has commenced outreach to provincial correctional health authorities in Alberta and Ontario. The company cited in-custody deaths attributed to inadequate withdrawal screening at intake, and said coroner jury recommendations issued in 2024 and 2025 call for clinical substance assessment tools at the point of admission. QScreen AI said the recommendations are directed to the relevant provincial ministries, which are obligated to respond within six months of issuance.
Management said the documented clinical need, ongoing coroner accountability processes, and the platform’s alignment with the recommendations support near-term evaluation discussions.
QScreen AI said it is advancing structured discussions in the US correctional health and national defense verticals following its previously announced engagement with Global Frontier Advisors L.P. (GFA). The company said GFA is led by Lieutenant General Michael S. Groen (Ret.), former Director of the US Department of Defense Joint Artificial Intelligence Center (JAIC), and that GFA’s compensation includes equity-based and performance-based components aligned with commercial milestones.
QScreen AI said approximately 4,800 federal, state, and local correctional facilities process 7.9 million jail admissions annually. It also stated that coroner’s juries across North America have recommended clinical substance assessment tools at intake. The company said GFA is advancing discussions with target facilities from an identified pipeline of 300 to 500 facility deployments.
The company said the US Department of Defense manages approximately 4,800 military sites worldwide. It stated that GFA is advancing discussions across personnel readiness screening and workforce health programs.
QScreen AI said approximately 50,000 Transportation Security Officers screen passengers at nearly 440 federalized airports nationwide. The company said the platform supports pre-shift physiological fitness for duty assessment without metabolite testing.
Dr. Rahul Kushwah, COO of QScreen AI Inc., said the company has built a platform that can tell a nurse in real time, using a camera, not only that someone is impaired but what they have consumed. He said the company has a patent, validated instruments, and 720,000 scans of real-world data behind its models, and that the platform is complete. Kushwah said the next milestone is a signed evaluation agreement.
QScreen AI Inc. is described as an emerging provider of rapid health screening and remote patient care solutions globally. The company said its Smarthealth AI stations use multispectral cameras and proprietary artificial intelligence to analyze physiological data patterns and predict a range of health issues, including 19 physiological vital parameters, impairment by drugs or alcohol, fatigue, and various mental illnesses. The company said its remote patient care platform provides medical professionals with AI-powered tools intended to improve patient health outcomes.
For more information, the company directs readers to www.q-screen.ai.
QScreen AI said the release may contain forward-looking statements based on current expectations, which involve risks and uncertainties that could cause actual results to differ materially. The company said it assumes no responsibility to update or revise such statements.
The company also stated that its screening tools provide risk assessment and decision support only and are not diagnostic medical devices, and are not intended to replace professional medical judgment.
The Canadian Securities Exchange said it has not reviewed nor does it accept responsibility for the adequacy or accuracy of the release.
Premium gym chains are entering a “golden era” that is ending or already in decline, as rising operating costs collide with shifting consumer preferences toward more flexible, community-based ways to exercise. Long-term memberships are shrinking, margins are pressured by higher rents and facility expenses, and competition from smaller, more personalized…
